Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPERO: Predictors of Response to Omalizumab in Allergic Asthma
NCT01922037Phase 4Completed
- Sponsor
- Roche
- Start
- Jun 2013
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Roche. Started Jun 2013; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01922037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01922037.